Clinical study to evaluate the IDO1 inhibitor therapy in canine bladder cancer

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K20609
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0605:Veterinary medical science, animal science, and related fields
• Research Institution: The University of Tokyo
• Principal Investigator: Ikeda Namiko 東京大学, 大学院農学生命科学研究科(農学部), 特任研究員 (60967339)
• Project Period (FY): 2022-08-31 – 2024-03-31
• Keywords: 犬膀胱癌 / IDO1 / アミノ酸代謝 / トリプトファン代謝 / 腫瘍免疫学 / キヌレニン / 腫瘍 / がん免疫療法

Outline of Final Research Achievements

Canine bladder cancer is a malignant tumor at the lower urinary tract. Even after surgery and medical therapy, most cases cause local recurrence or distant metastasis, leading to death within 1-2 years of tumor onset.
In this study, a clinical trial of an inhibitory against indoleamine 2,3-dioxygenase 1 (IDO1), an amino acid metabolising enzyme discovered by the principal investigator of this grant as a new therapeutic target for canine bladder cancer, was conducted at the Department of Surgery, University of Tokyo, Veterinary Medical Centre, and succeeded in demonstrating that the IDO1 inhibitor therapy is effective in canine bladder cancer and has potential as a new systemic therapy.

Free Research Field

腫瘍免疫療法

Academic Significance and Societal Importance of the Research Achievements

犬膀胱癌は予後が悪く、新たな全身療法の確立が求められている。本研究では少数例であるが臨床試験を実施し、犬膀胱癌に対するIDO1阻害療法の臨床的な有効性の実証に成功し、IDO1阻害療法が犬膀胱癌の予後を改善する新たな全身療法となる可能性を実証した。
さらに、IDO1は犬膀胱癌以外の犬悪性腫瘍においても発現しており、また各種ヒト悪性腫瘍においても発現していることから、本研究成果は獣医学領域および医学領域における発展性を有し、その価値は大きい。